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patients with long QT syndrome type 3 (LQT3) has been repeatedly
questioned, and it has been suggested that they might be detri-
mental for this genetic subgroup of patients with long QT syndrome
(LQTS). The disquieting consequence has been that cardiologists
confronted with LQT3 patients often do not even attempt pharmaco-
logic therapy and implant cardioverter-deﬁbrillators as ﬁrst-choice
treatment. However, the most recent clinical data indicate high
efﬁcacy of beta-blocker therapy in LQT3 patients.
OBJECTIVE The purpose of this study was to test the antiarrhyth-
mic efﬁcacy of beta-blockers in an established experimental model
for LQT3.
METHODS After phenotypic validation of 65ΔKPQ-SCN5A knock-in
transgenic (TG) mice compared to 32 wild-type (WT) mice, we
tested the effect of the arrhythmogenic cholinergic muscarinic
agonist carbachol in 19 WT and 39 TG anesthetized mice, with and
without pretreatment with propranolol given intraperitoneally.
RESULTS At the same heart rates, TG mice had a markedly longer
QT interval than WT mice. Whereas carbachol had minor arrhythmic☆The ﬁnancial support of Telethon–Italy (Grant No. GGP 09247) is
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1547-5271 B 2014 Heart Rhythm Society. Open access under CC BY-NC-ND licenseeffects in the WT mice, it produced ventricular tachycardia (VT) and
ventricular ﬁbrillation (VF) in 55% of 20 TG mice. By contrast, in
none of 19 TG mice pretreated with propranolol did VT/VF occur
after carbachol injection.
CONCLUSION These experimental data indicate that, contrary to
previous reports, beta-blockade effectively prevents VT/VF in a
validated LQT3 model. Together with the most recent clinical data,
these ﬁndings indicate that there is no reason for not initiating
protective therapy with beta-blockers in LQT3 patients.
KEYWORDS Long QT syndrome type 3; Beta-blocker; Transgenic
mice; Sudden death
ABBREVIATIONS HR ¼ heart rate; ICD ¼ implantable cardioverter-
deﬁbrillator; IP ¼ intraperitoneal; LQT3 ¼ long QT syndrome type
3; LQTS ¼ long QT syndrome; TG ¼ transgenic; VF ¼ ventricular
ﬁbrillation; VPB ¼ ventricular premature beat; VT ¼ ventricular
tachycardia; WT ¼ wild type
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Open access under CC BY-NC-ND license.Among patients affected by long QT syndrome (LQTS) and
who have been positively genotyped, those with gain-of-
function mutations on the SCN5A gene, which causes an
increase in the delayed Naþ inward current, represent
approximately only 10% but constitute the most difﬁcultsubgroup to manage.1 Since the beginning of genotype–
phenotype correlation studies, it was reported that the
occurrence of sudden death was higher among patients with
long QT syndrome type 3 (LQT3).2,3 Moreover and of major
concern, it was said that beta-blockers were largely ineffec-
tive in preventing their life-threatening arrhythmias4–6 and
was at variance especially with LQT1 patients.4,5,7
A disquieting consequence of this concept was that too
often the simple genetic diagnosis of LQT3 led to placement
of an implantable cardioverter-deﬁbrillator (ICD), even among
patients who still were asymptomatic.8,9 Also, beta-blockerhttp://dx.doi.org/10.1016/j.hrthm.2013.10.029.
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the assumption that beta-blockers were ineffective. This view
was based on rather small numbers of LQT3 patients but was
also supported by experimental data obtained from cellular
preparations10 and in transgenic (TG) mice.11
The concept of the lack of efﬁcacy of beta-blockers for
LQT3 patients was challenged when, based on a small
population, it was pointed out that this apparent failure was
the consequence of having lumped together all LQT3
patients, including those who had suffered a cardiac arrest
in the ﬁrst year of life.12 From this analysis it emerged that
whereas LQT3 patients with events in infancy represent a
subgroup at extremely high risk and largely unresponsive to
therapy, those without early events appeared to be well
protected by beta-blockers.12
We decided to reassess whether beta-blockers are inef-
fective against the arrhythmias that occur in the presence of
an SCN5A mutation using an established whole animal
model, the heterozygous ΔKPQ-SCN5A knock-in TG mice.
Our ﬁndings indicate that, contrary to the prevailing opinion
but in agreement with the most recent clinical data,13,14 beta-
blockers are very effective against the life-threatening
arrhythmias of LQT3.Methods
The murine model of LQT3 used in our study has been
previously described in detail11,15and was kindly donated by
Peter Carmeliet. Heterozygous ΔKPQ-SCN5A knock-in TG
mice were characterized and compared with wild-type (WT)
littermate mice. All of the animals were adult males (average
age 6 months, weight 40 g). The mice were anesthetized with
Avertin 0.015 mL/g intraperitoneal (IP) injection,16 and the
experiments were terminal.ECG recordings and measurements
ECG recording started 2 minutes after onset of anesthesia
while the mice were placed on a heating pad with continuous
monitoring of body temperature. Five needle electrodes (one
electrode implanted subcutaneously in each limb and one
placed in the precordial position) connected to AD Instru-
ments Ltd, (Oxford, UK) ampliﬁers set with bandpass
ﬁltering between 0.03 and 1 kHz were used for six-lead
ECG recording.
ECG parameters (heart rate [HR], RR and QT intervals)
were analyzed blindly to genotype. Measurements were
performed using the signal-averaged ECG (mouse SAECG
v1.2 program, AD Instruments) through a template-matching
algorithm. QT interval (from onset of QRS complex to return
to baseline of T wave) was measured in lead I. The remaining
leads were mainly used to validate what was observed in lead I
(i.e., ventricular arrhythmias, prolonged QT, etc.).
Cardiac arrhythmias were classiﬁed by the most severe
episode as absent, minor (isolated ventricular premature beats
[VPBs], couples of VPBs, ventricular bigeminy), or major
(ventricular tachycardia [VT], ventricular ﬁbrillation [VF]).Study protocol
Our investigation follows the Guidelines for the Care and
Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85-23, revised
1996) and was approved by the Ethics Review Board of the
Italian Ministry of Health. All procedures were performed in
accordance with the animal care guidelines of the Federation
of Laboratory Animals Science Associations. After baseline
ECG variables were recorded, all mice, still under anesthesia,
were assigned to one of the two arms of the study. The mice
either were injected with the cholinergic agonist carbachol or
were pretreated with propranolol followed 2 to 3 minutes
later by carbachol injection. All animals were monitored
continuously by ECG for up to 30 minutes after the
administration of carbachol until the end of the experiment.
All drugs used were provided by Sigma-Aldrich Srl, Milan,
Italy and AstraZeneca SpA, Basiglio, Italy.Pharmacologic interventions
The cholinergic agonist carbachol (carbamylcholine chloride
0.5 mg/kg) was administered IP in all mice. Within 1 to 2
minutes of injection, HR decreased from baseline. We
selected a 2-minute good-quality ECG tracing to obtain
HR and QT measurements following carbachol. ECG
monitoring continued up to 30 minutes to assess the potential
occurrence of arrhythmic events.
After the baseline ECG variables had been recorded,
propranolol 0.1 mg/kg was injected IP Two to three minutes
after the injection, a 6% to 9% decrement in HRwas achieved,
and HR and QT measurements on propranolol were made.
Carbachol was then injected, and ECG monitoring continued
for up to 30 minutes to observe arrhythmic events.
Genotyping was performed using a speciﬁc custom Taq-
Man assay (Life Technologies Italia, Monza, Italy) to
discriminate between WT and mutant SCN5A sequence on
a 7900 HT fast real-time polymerase chain reaction instru-
ment (Life Technologies).Statistical analysis
Continuous variables are given as mean  SD and were
compared among groups deﬁned by genetic status and treat-
ment protocol using the unpaired Student t test or analysis of
variance, as appropriate. Whenever assumptions of normality
and homogeneity of variance were questionable, the equivalent
nonparametric tests (Mann-Whitney or Kruskal-Wallis test for
independent samples) were used. Similarly, changes of basal
ECG parameters after drug exposure within genetic groups
were analyzed with t test or Wilcoxon signed rank test for
paired samples. Categorical variables are expressed as absolute
and relative frequencies and were analyzed by χ2 or Fisher
exact test. Post-treatment survival to the primary endpoint of
VT/VF was described by Kaplan-Meier cumulative estimates,
with comparison performed by the log rank test. Po.05 (two-
sided) was considered signiﬁcant. All analyses were made
using SPSS Statistics (version 19, IBM Italia SpA, Italy).
Figure 1 Outline of the study population subdivided into subgroups
according to intervention protocol and genotyping. TG ¼ transgenic; WT¼
wild type.
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The study population, divided into subgroups by pharmaco-
logic intervention and genotype, is shown in Figure 1.
Basal ECG
Basal ECG was recorded in 97 mice (65 TG and 32 WT).
Phenotypic characterization conﬁrmed that, compared to
their WT littermates, TG mice had a signiﬁcantly more
prolonged QT interval (77 12 ms vs 61 6 ms, Po.001)
and a signiﬁcantly lower mean basal HR (340  52 bpm vs
371  47 bpm, P ¼ .005). Given the observed difference in
basal HR between TG and WT animals and the established
relationship between RR and QT intervals, we also compared
the QT at ﬁxed ranges of RR intervals (140–159 ms, 160–
179 ms, 180–199 ms, and 200–220 ms) to control for QT
adaptation, as it is done in infants.17 As expected, at all
predeﬁned RR ranges, TG mice showed a signiﬁcantly
(Po.001 for all comparisons) longer QT interval compared
to WT mice (69  8 ms, 76  9 ms, 79  10 ms, and 83 
10 ms vs 58 5 ms, 60 6 ms, 65 5 ms, and 68 8 ms,
respectively; Table 1 and Figure 2).
Effect of drugs on ECG
Fifty-eight mice (39 TG and 19 WT) underwent pharmaco-
logic experiments to evaluate the proarrhythmic effect of
carbachol and the potential protective role of propranolol




TG-ΔKPQ mice Basal QT in WT mice P value
140–159 69  8 (37) 58  5 (25) o.001
160–179 76  9 (47) 60  6 (22) o.001
180–199 79  10 (50) 65  5 (20) o.001
200–220 83  10 (42) 68  8 (14) o.001
Number of mice with available measure is reported in parentheses.
TG ¼ transgenic; WT ¼ wild type.treated with carbachol alone (groups 1 and 3), whereas
19 TG and 10 WT mice were pretreated with propra-
nolol and then injected with carbachol (groups 2 and 4;
Figure 1).
Whereas mean basal HR was conﬁrmed to be signiﬁ-
cantly lower in the 39 TG mice compared to the 19 WT
animals (352  52 bpm vs 383  49 bpm, P o.05), no
signiﬁcant difference in HR was observed across the four
groups (P ¼ .10; Table 2). Mean values of basal QT interval
were almost identical within both TG subgroups (76 15 ms
in group 1 and 76  12 ms in group 2) and within both WT
groups (60  6 ms in group 3 vs 62  5 ms in group 4). As
expected, each TG subgroup had a signiﬁcantly (P o.05)
longer QT interval compared to its corresponding WT
counterpart.
Compared to baseline values, carbachol treatment sig-
niﬁcantly decreased HR and prolonged QT interval in all
mice (Table 2). The relative (%) change from baseline of
both HR and QT following carbachol was rather similar
across the four subgroups, independent of genotype or
propranolol pre-treatment (HR: 47%  11%, 53%  16%,
54%  12%, 59%  10%, P ¼ .07; QT: 39%  29%,
54%  34%, 69%  37%, 64%  31%, P ¼ .1).Arrhythmic events
The occurrence of cardiac arrhythmias according to geno-
type and drug exposure is summarized in Figure 3.
In the TG ΔKPQ-SCN5A mice, the overall incidence of
drug-induced arrhythmias was high (27/39 [69%]) but with
striking differences between groups 1 and 2. Speciﬁcally, in
group 1, of the 20 TG mice injected only with carbachol, 4
(20%) had no arrhythmias, 5 (25%) showed minor events
(VPBs), and 11 (55%) developed major arrhythmias (VT
and/or VF), which occurred at a median time of 11 minutes
(interquartile range 9–21) after carbachol injection. By
contrast, in group 2, among the 19 TG mice pretreated with
propranolol and then injected with carbachol, none devel-
oped major arrhythmias; isolated VPBs were observed in 11
mice (58%), and 8 (42%) had no cardiac arrhythmias
(Figure 3A). Therefore, pre-treatment with propranolol had
a marked and signiﬁcant (Po.001) effect on the occurrence
of major arrhythmias among TG mice as it was associated
with the total absence of VT/VF compared to TG mice not
pretreated with propranolol (i.e., with 100% cumulative
survival to VT/VF compared to 39%; Figure 4).
Among the WT mice overall, only minor arrhythmias
were observed after the pharmacologic interventions, and
this occurred in 9 of 19 (47%). Speciﬁcally, in group 3, of the
nine mice treated with carbachol, 5 (56%) had isolated VPBs
whereas none developed major arrhythmias (VT/VF;
Figure 3B). Similarly, in group 4 none of the 10 WT mice
pretreated with propranolol and then injected with carbachol
had major arrhythmias, whereas four developed isolated
VPBs and six had no arrhythmias at all (Figure 3B). Thus,
among theWTmice, all carbachol-induced arrhythmias were
minor and unaffected by propranolol (P ¼ .66; Figure 3).
Figure 2 ECG tracings of one wild-type (WT) and
two transgenic (TG) mice. A: WT mouse, RR 117
ms, basal heart rate (HR) 513 bpm, QT 60 ms. B: TG
Mouse, RR 119 ms, basal HR 506 bpm, QT 74 ms.
C: TG mouse, 6 minutes after 0.5 mg/kg carbachol
intraperitoneal. A and B illustrate the longer QT
interval, for the same HR, present in TG vsWTmice.
C shows the occurrence of what looks like an episode
of torsades de pointes ventricular tachycardia in a TG
mouse exposed to carbachol.
Table 2 Heart rate and QT interval before and after propranolol and/or carbachol injections in TG and WT mice
TG WT
P value**Group 1* (n ¼ 20) Group 2* (n ¼ 19) Group 3* (n ¼ 9) Group 4* (n ¼ 10)
Pre-treatment measurements
Basal HR (bpm) 360  61 344  39 395  65 372  29 .10
Basal QT (ms) 76  15† 76  12† 60  6 62  5 o.001
Post-treatment measurements
HR postpropranolol (bpm) 313  42 351  30 .02
QT postpropranolol (ms) 81  12 66  9 .002
HR postcarbachol (bpm) 187  35‡ 159  48‡ 177  36‡ 153  40‡ .09
QT postcarbachol (ms) 106  35‡ 116  32‡ 100  22‡ 100  20‡ .48
HR ¼ heart rate.
*Group 1 ¼ ΔKPQ transgenic mice treated with carbachol; group 2 ¼ ΔKPQ transgenic mice treated with propranolol and carbachol; group 3 ¼ wild-type (WT)
mice treated with carbachol; group 4 ¼ WT mice treated with propranolol and carbachol.
**P values from analysis of variance or unpaired t test.
†P o.05 TG mice groups 1 and 2 vs corresponding groups 3 and 4 WT counterparts, after post hoc Bonferroni test for multiple comparisons.
‡P o.001 vs corresponding baseline measurement.
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Figure 3 Carbachol-induced arrhythmias in transgenic (TG; A) and wild-
type (WT; B) mice with and without pretreatment with propranolol. VF ¼
ventricular ﬁbrillation; VPB¼ ventricular premature beat; VT¼ ventricular
tachycardia.
Figure 4 Cumulative survival to major arrhythmias (ventricular tachycar-
dia/ventricular ﬁbrillation [VT/VF]) in transgenic mice according to protocol
treatment.
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The present study demonstrates that propranolol effectively
prevents carbachol-induced life-threatening arrhythmias in
an established animal model for LQT3. The cholinergic
stimulation produced by carbachol causes bradycardia and
cardiac arrhythmias in vivo in this reliable experimental
preparation, which presents the classic features of LQT3 in
the clinic.11,15,18 The striking protection afforded by propra-
nolol mirrors the latest clinical observations in LQT3
patients and forces a reassessment of the previous assump-
tions that have caused so much harm to some of these
patients.
Previous clinical data
Identiﬁcation of the major LQTS genes in the mid-1990s1
has had a major impact on clinical management.19 A
negative consequence has been the pressure on all inves-
tigators (present ones included) to publish, as soon as
possible, their own data on genotype–phenotype correlation.
Genotyped patients providing data on the effect of therapy
initially were scanty, and this resulted in publications with
very limited numbers but nonetheless conveying important
messages. In 2000, Moss et al6 reported the effect of beta-
blockers in 869 LQTS patients, of whom 139 had been
genotyped. Of the 28 LQT3 patients, only four had cardiac
events before therapy, and the conclusion was “Although the
number of patients with LQT3 is quite small and the event
rates in this genotype are quite low, no beneﬁcial beta-blocker effect was evident in LQT3.”6 This was followed by
two larger studies that conveyed the same message. In 2001,
Schwartz et al4 reported on 670 genotyped patients, all with
cardiac events; 65 (9.7%) were LQT3 patients. Among those
on beta-blocker therapy, mortality was 4% for both LQT1
and LQT2 patients but reached 17% for LQT3 patients. Even
though only 18 patients were in this group, it was concluded
that “LQT3 patients are at higher risk at longer cycle
lengths. This raises concerns, not yet supported by evidence,
regarding the use of beta-blockers because of the attendant
reduction in heart rate.”4 In 2004, Priori et al5 reported on
335 genotyped LQTS patients, of whom 28 (8.3%) were
LQT3. Cardiac arrests on beta-blocker therapy were more
frequent (14%) in LQT3 than LQT1 (1%) and LQT2 patients
(7%). They suggested that “prophylactic deﬁbrillator ther-
apy may be a reasonable addition to beta-blockers in
patients with LQT2 or LQT3 genotypes.”5 These convergent
messages, despite all being based on limited numbers and
expressed cautiously, led many cardiologists to the unwar-
ranted conclusion that beta-blockers were not protecting
LQT3 patients. The unfortunate consequence has been the
high number of LQT3 patients who received a prophylactic
ICD despite being asymptomatic and without having ever
been treated with beta-blockers.9
Eventually, we realized that this concept was not ﬁtting
with our personal clinical experience, and the analysis of
individual outcomes unmasked an important and striking
difference: whereas patients with cardiac events in the ﬁrst
year of life had a very poor prognosis and died soon, those
who were asymptomatic in their ﬁrst year were very well
protected by beta-blockers.12 Our breakthrough has just been
conﬁrmed by the largest study ever performed in LQT3
patients (n ¼ 403), which demonstrates that among those
without events in the ﬁrst year of life mortality on beta-
blockers is just close to 3%.13 Thus, the available clinical
data indicate clearly that beta-blockers are very effective for
LQT3 patients as well, with the exception of the small
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left cardiac sympathetic denervation.12,20–22Previous experimental data
While rumors about the lack of efﬁcacy of beta-blockers for
LQT3 patients were spreading in the cardiology community,
two experimental studies appeared and claimed to “closely
mirror the clinical experience”10 and to “conﬁrm the clinical
observation that LQT3 patients do not beneﬁt from beta-
blocker therapy.”11
Shimizu and Antzelevitch10 used their arterially perfused
wedge of canine ventricle and, having modeled LQT3,
reported beneﬁcial effects of sympathetic stimulation (by
isoproterenol) that were abolished by propranolol. Their
conclusion that “b-blockade might be contraindicated in
LQT3” had a signiﬁcant impact on the clinical decisions of
the subsequent years. The problem with their study was the
assumption that isoproterenol, a nonbiologic substance, would
mimic what happens in real life when there is a sudden
increase in sympathetic activity. Reality is different. During
progressive sympathetic activation, as occurs during exercise,
blood-borne epinephrine has a dominant effect and, because
of its simultaneous effect on all cardiac cells, reduces electrical
heterogeneity and increases electrical stability. What happens
experimentally with isoproterenol is similar, but stimulation is
limited to the beta-receptors. By contrast, sudden centrally
mediated sympathetic activation elicits a mostly localized
release of norepinephrine from neural terminals, which
increases both regional heterogeneity and cardiac electrical
instability. This explains the profound difference in the
correlation between sudden death and HR responses during
exercise and mental stress.23 Thus, it had to be expected that
uniform beta-adrenergic stimulation by isoproterenol perfu-
sion would reduce the dispersion of repolarization caused by
anthopleurin (which augments late INa), and that this “bene-
ﬁcial” effect produced by stimulation of beta-adrenergic
receptors would be prevented by propranolol, a drug whose
function is blocking the beta-receptors. We do not believe that
the interaction between isoproterenol and propranolol in
isolated tissue preparations justiﬁes assumptions on the
antiarrhythmic efﬁcacy of propranolol in patients exposed to
sudden neurally mediated release of norepinephrine.
Fabritz et11 al used the same model of the present study
and reported that propranolol did not prevent the arrhythmias
induced by carbachol. We do not have a ready explanation
for these different results, as sometimes occurs among
laboratories. We can only point to some experimental
difference, such as propranolol assumed by drinking water
vs injected IP and an ambulatory vs anesthetized state.
However, a major and potentially important difference is the
number of TG animals tested with carbachol plus proprano-
lol, which was 19 mice in the present experiments and only
four in those by Fabritz et al.11
When experimental results differ, it is an old and good rule
to verify what happens in the patients. It is now evident, based
on adequate numbers, that beta-blockers are very effective inprotecting LQT3 patients from life-threatening arrhyth-
mias.12–14 The exception represented by infants with cardiac
arrest in the ﬁrst year of life does not impact on the concept.12
The present experiments
The present experiments have been rather straightforward.
We used a well-validated animal model for LQT3,11,15,18
conﬁrmed its characteristic QT prolongation, reproduced
VT/VF by the muscarinic agonist carbachol, and observed
that propranolol-pretreated mice did not develop VT/VF
after carbachol. We repeated these interventions in WT mice
and observed modest effects of carbachol essentially
unmodiﬁed by propranolol. The efﬁcacy of propranolol
likely reﬂects the combination of beta-adrenergic blockade
with its well-known “membrane stabilizing” effect, which
includes signiﬁcant reductions in both peak and late Naþ
current. This effect is present but modest for nadolol and is
completely absent for metoprolol.24 Indeed, we believe that
for LQT3 patients, propranolol should be regarded the beta-
blocker of choice.
The decrease in HR produced by propranolol and its
modest effect on QT interval were as expected given that we
looked at the QT as measured and not at the QTc to avoid the
overcorrection associated with very short RR intervals.
When carbachol produced VT/VF in the TG mice, most of
the arrhythmias occurred within 15 min from the injection.
The Kaplan–Meier curve provides a graphic evidence of the
protective effect of propranolol in these LQT3 animals.
Study limitations
Even though the IP dose of propranolol per kilogram is the
same as that given intravenously in man, it is fair to
remember that beta-blocker therapy in LQTS patients is
administered orally. Therefore, some difference in the
magnitude of the effects cannot be ruled out. Also, we
studied the effect of propranolol in one speciﬁc, albeit fairly
representative, SCN5A mutation; accordingly, we cannot
exclude that with different mutations one could observe
different degrees of protection, as we already reported.25
Clinical implications
These experimental results carry clinical implications. They
should help dispel, once and for all, the concern that beta-
blockade provides no protection against VT/VF occurring in
experimental models for LQT3 and thereby also in patients.
Furthermore, when taken together with the most recent
clinical data, these observations send a clear and unequivocal
message to practicing cardiologists that LQT3 patients
should be placed on beta-blocker therapy as ﬁrst choice
without hesitation,14 with preference given to propranolol.Acknowledgments
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